

Cycle Control

Question 20. Do the members of the Advisory Committee agree with the recommendations for standardization of data collection and analysis of bleeding in combined hormone contraceptive trials proposed in the article by Mishell et al.?

Question 21. How should the Division assess the impact of unscheduled bleeding on product acceptability?

Question 22. What objective measures beyond hemoglobin and hematocrit values, if any, should be employed to assess significant change in hematologic status?